Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. BioRestorative Therapies's Revenue for the
three
months ended in Mar. 2026 was €0.02 Mil. BioRestorative Therapies's average Accounts Receivable for the
three
months ended in Mar. 2026 was €0.01 Mil.
Hence, BioRestorative Therapies's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.60.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
BioRestorative Therapies Receivables Turnover Related Terms
BioRestorative Therapies Receivables Turnover Historical Data
* Premium members only.
The historical data trend for BioRestorative Therapies's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:9OF vs CVKD, JSPR, APRE: Receivables Turnover Comparison
For the Biotechnology subindustry, BioRestorative Therapies's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRestorative Therapies Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where BioRestorative Therapies's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioRestorative Therapies (FRA:9OF) has a Receivables Turnover of 1.60 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BioRestorative Therapies and its competitors. According to the industry distribution chart, BioRestorative Therapies ranks #67 out of 841 companies in the Biotechnology industry, placing it in the top 8%.
Is BioRestorative Therapies' Receivables Turnover too high?
BioRestorative Therapies' current Receivables Turnover is 1.60. The Biotechnology industry median Receivables Turnover is 5.29. BioRestorative Therapies' value of 1.60 is 69.8% below this industry median. Based on the distribution chart, BioRestorative Therapies ranks #67 out of 841 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioRestorative Therapies has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' Receivables Turnover compare to CVKD and JSPR?
According to the Biotechnology industry distribution chart, BioRestorative Therapies ranks #67 out of 841 companies for Receivables Turnover. This places BioRestorative Therapies in the top 8% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.29. BioRestorative Therapies' value of 1.60 is 69.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioRestorative Therapies's current Receivables Turnover of 1.60 is 69.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BioRestorative Therapies and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioRestorative Therapies's current Receivables Turnover is 1.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (FRA:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.31, compared to a current price of €0.29 — trading 77.6% below its estimated fair value. The current Receivables Turnover is 1.60 and 69.8% below the Biotechnology industry median of 5.29. BioRestorative Therapies' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For BioRestorative Therapies (FRA:9OF), the current Receivables Turnover is 1.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioRestorative Therapies (FRA:9OF) Overvalued in 2026?
Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued.
The current stock price of €0.29 is trading 77.6% below its estimated GF Value™ of €1.31.
GuruFocus considers BioRestorative Therapies to be Possible Value Trap.
Key valuation signals for FRA:9OF:
Receivables Turnover: 1.60
GF Value™: €1.31 vs. price of €0.29 (77.6% below fair value)
Industry Position: 69.8% below the Biotechnology median (#67 of 841)
No single metric tells the full story. See the FRA:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
55GF Score
Get the complete analysis for FRA:9OF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9OF has been successfully added to your 
